{"id":1397,"date":"2010-01-06T17:50:44","date_gmt":"2010-01-06T22:50:44","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/wednesday-news-roundup-fda-to-reevaluate-esas-aspirin-underuse-in-reach-more\/"},"modified":"2011-07-19T17:45:06","modified_gmt":"2011-07-19T21:45:06","slug":"wednesday-news-roundup-fda-to-reevaluate-esas-aspirin-underuse-in-reach-more","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/01\/06\/wednesday-news-roundup-fda-to-reevaluate-esas-aspirin-underuse-in-reach-more\/","title":{"rendered":"Wednesday News Roundup: FDA to Reevaluate ESAs, Aspirin Underuse in REACH, &amp; more&#8230;"},"content":{"rendered":"<p>In an <a href=\"http:\/\/healthcarereform.nejm.org\/?p=2636&amp;query=home\">NEJM\u00a0perspective<\/a>, four FDA officials review the sorry history of erythropoiesis-stimulating agents (ESAs) and call for randomized trials to establish &#8220;the optimal hemoglobin target, dosing algorithm, and monitoring approach&#8221; for these drugs. They also announce that the FDA intends to convene an advisory panel in 2010 &#8220;to reevaluate the use of ESAs in the treatment of anemia due to chronic kidney disease.\u201d<\/p>\n<p>One-quarter of US patients with vascular disease are not receiving aspirin for secondary prevention, according to <a href=\"http:\/\/dx.doi.org\/10.1016\/j.amjcard.2009.10.014\">a report by Chris Cannon et al from the REACH Registry published online in the <em>American Journal of Cardiology<\/em><\/a>.<\/p>\n<p>The FDA gave guidance to <a href=\"http:\/\/investors.aryx.com\/ReleaseDetail.cfm?ReleaseID=434146\">ARYx Therapeutics (press release) <\/a>on the development path for its anticoagulant tecarfarin, which stumbled last summer in a test against warfarin.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In an NEJM\u00a0perspective, four FDA officials review the sorry history of erythropoiesis-stimulating agents (ESAs) and call for randomized trials to establish &#8220;the optimal hemoglobin target, dosing algorithm, and monitoring approach&#8221; for these drugs. They also announce that the FDA intends to convene an advisory panel in 2010 &#8220;to reevaluate the use of ESAs in the [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1397","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1397"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1397\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}